Video

Dr. Plimack Discusses Recent Trials in Kidney Cancer

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses recent trials in kidney cancer.

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses recent trials in kidney cancer.

In findings from the phase III IMmotion151 study presented during the 2018 Genitourinary (GU) Cancers Symposium, the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) reduced the risk of progression or death by 26% compared with sunitinib (Sutent) for patients with untreated PD-L1—positive metastatic kidney cancer. This is one of the first trials of VEGF inhibition with PD-1 inhibition to read out, says Plimack.

Long-term single-arm data with the combination of axitinib (Inlyta) and pembrolizumab (Keytruda), another immunotherapy combination, was also recently presented at the 2018 GU Cancers Symposium. The combination showed superior antitumor activity to that expected from axitinib or PD-1/PD-L1 pathway inhibitor monotherapy in treatment-naïve patients with advanced kidney cancer. Best overall response was a complete response in 4 patients (7.7%), partial response in 34 (65.4%), and stable disease in 8 (15.4%). The median progression-free survival was 20.9 months (95% CI, 15.4-not evaluable).

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity